Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease;Effets de l'association de la sulbutiamine à un inhibiteur de l'acétylcholinestérase dans les formes légères à modérées de la maladie d'Alzheimer

Encephale

Volumn 33, Issue 2, 2007, Pages 211-215

  Ollat, H ^a   Laurent, B ^b   Bakchine, S ^c   Michel, B F ^d   Touchon, J ^e   Dubois, B ^f  

^a Assoc pour Neuro Psycho P   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c HÔPITAL MAISON BLANCHE   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e GUI DE CHAULIAC HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer disease; Attention disorders; Executive disorders; Memory disorders; Sulbutiamine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; SULBUTIAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; EPISODIC MEMORY; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKING MEMORY;

EID: 34249073031     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(07)91552-3     Document Type: Article

References (21)

1. th Edition). American Psychiatric Association. USA : Washington DC, 1994.
2. th Edition). New York : Psychological Corporation, 1974.
3. BETTENDORFF L, WEEKERS L, WINS P et al. Injection of Sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem Pharmacol 1990 ; 40 (11) : 2557-60.
4. BIZOT JC, HERPIN A, POTHION S et al. Chronic treatment with Sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task. Prog Neuropsychopharmacol Biol Psychiatry 2005 ; 29 (6) : 928-35.
5. th ed.] Göttingen : Verlag für Psychologie Dr Hogrefe CJ ; 1981.
6. CARDEBAT D, DOYON B, PUEL M et al. Évocation lexicale formelle et sémantique chez des sujets normaux. Performances et dynamiques de production en fonction du sexe, de l'âge et du niveau d'étude. Acta Neurol Belg 1990 ; 90 : 207-17.
7. COREY-BLOOM J, ANAND R, VEACH J. For the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 ; 1 : 55-65.
8. CUMMINGS JL, MEGA M, GRAY K et al. The Neuropsychiatry Inventory : Comprehensive assessment of psychopathology in dementia. Neurology 1994 ; 44 : 2308-14.
9. DU BOITESSELIN R, HUN M. Étude histochimique de l'imprégnation des formations cérébrales après administration de sulbutiamine. Synthèse Med 1985 ; 309 : 11-2.
10. DEROUESNÉ C, De ALBERTO MJ, BOYER P et al. Empirical evaluation of the cognitive difficulties scale for the assessment of memory complaints in general practice. Study of 1 628 cognitively normal subjects aged 45-75 years. Int J Geriatr Psychiatric 1993 ; 8 : 599-607.
11. FOLSTEIN MF, FOLSTEIN SE, McHUGH PR. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 ; 12 : 189-98.
12. McKHANN G, DRACHMAN D, FOLSTEIN M et al. Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer' disease. Neurology 1984 ; 34 : 39-44.
13. MICHEAU J, DURKIN TP, DESTRACE C et al. Chronic administration of Sulbutiamine improves long term memory formation in mice ; possible cholinergic mediation. Pharmacol Biochem Behav 1985 ; 23 (2) : 195-8.
14. MONTGOMERY SA, ASBERG M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 ; 134 : 382-9.
15. RASKIN MA, PESKIND ER, WESSEL T et al. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000 ; 54 : 2261-8.
16. REITAN RM. Validity of the Trail Making Test as an indication of organic brain damage. Perceptual and Motor Skills 1958 ; 8 : 271-6.
17. ROGERS SL, FARLOW MR, DOODY RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998 ; 50 : 136-45.
18. ROSEN WG, TERRY RD, FULD PA et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980 ; 7 : 486.
19. TROVERO F, GOBBI M, WEIL-FUGGAZA J et al. Evidence for a modulatory effect of sultubiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neurosci Lett 2000 ; 292 (1) : 49-53.
20. VAN DER LINDEN M, COYETTE F, POITRENAUD J et al. L'épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16). In : Van der Linden M, et le GREMEM (eds). L'évaluation des troubles de la mémoire. Marseille : Solal, 2004 : 25-47.
21. WECHSLER D. WAIS-R manual. New-York : Psychological Corporation, 1981.